ProtoKinetix, Incorporated (PKTX) Research

ProtoKinetix, Incorporated is a biotechnology firm engaged in research and development, specializing in the scientific and medical investigation of glycoproteins known as anti-freeze glycoproteins (AFGPs) and anti-aging glycoproteins (AAGPs). These AFGPs are particularly relevant for their commercial potential within the healthcare sector, with a key area of their development involving utilizing AAGPs for the treatment of dry-eye conditions. Their research efforts are bolstered by a collaborative agreement with the University of British Columbia. Originally incorporated in 1999 as RJV Network, Inc., the company adopted its current name, ProtoKinetix, Incorporated, in July 2003. Its operational headquarters are situated in Marietta, Ohio.

Market snapshot

Symbol
PKTX
Price
$0.01
Day change
+8.08%
Market cap
$2.2M
P/E ratio
-5.82x
52-week range
0.004-0.0124
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • Algernon Pharmaceuticals Inc. (AGNPF)
  • Acrux Limited (ARUXF)
  • AXIM Biotechnologies, Inc. (AXIM)
  • HAVN Life Sciences Inc. (HAVLF)
  • Universal Ibogaine Inc. (IBOGF)
  • Radient Technologies Inc. (RDDTF)
  • RepliCel Life Sciences Inc. (REPCF)
  • ReNeuron Group plc (RNUGF)

Recent insider activity

  • SMITH CLARENCE EDWARD — P-Purchase (2000000 shares) on 2024-09-26
  • SMITH CLARENCE EDWARD — P-Purchase (3100000 shares) on 2024-06-14
  • SMITH CLARENCE EDWARD — P-Purchase (3400000 shares) on 2024-06-13
  • SMITH CLARENCE EDWARD — P-Purchase (2500000 shares) on 2024-03-29
  • SMITH CLARENCE EDWARD — P-Purchase (666667 shares) on 2024-03-20

Open ProtoKinetix, Incorporated (PKTX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.